GHRP-2 is one of the classic growth-hormone-releasing peptides, frequently
studied and discussed alongside GHRP-6 and the GHRH analogs.
Chemical identity & structure.
GHRP-2 (growth hormone releasing peptide-2) is a synthetic hexapeptide. Like the
other GHRPs it is a ghrelin mimetic — a growth hormone secretagogue receptor
(GHS-R) agonist — not a GHRH analog. It is a small, defined peptide.
Mechanism of action.
GHRP-2 agonizes the GHS-R to trigger a pituitary growth hormone pulse. It also
has a modest appetite-stimulating effect through the same ghrelin-pathway
mimicry, and is reported to produce some increase in cortisol and prolactin,
though less pronounced than older secretagogues. It is frequently studied in
combination with a GHRH analog because the two receptor pathways are
complementary and produce a larger combined GH pulse than either alone.
Key research findings.
GHRP-2 has been studied as a GH secretagogue, including as a diagnostic tool for
assessing pituitary GH-release capacity. The literature documents reliable
GH-release stimulation and the synergy with GHRH-pathway agonists.
The research / citation base.
GHRP-2 is not an approved drug in most jurisdictions; it has seen some
diagnostic clinical use. Its evidence base is clinical pharmacology and
preclinical research rather than large efficacy-outcome trials.
Research protocols in the literature.
Research has used subcutaneous administration of reconstituted lyophilized
peptide, often in the GHRH-plus-GHRP combination context. GH secretion is
pulsatile, so pulse timing is a recurring theme.
Quality & sourcing notes.
A batch-specific COA with mass-spectrometry identity and HPLC purity is
essential. The GHRP peptides are small and easily confused — confirm the COA
describes GHRP-2 specifically and not GHRP-6 or hexarelin.
*Research-use note: Educational summary of published research. GHRP-2 is not a
broadly approved drug; this is research context only and not medical advice.*